Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author.

Get the power of Which? in your pocket by downloading our app, giving you on-the-go access to our reviews ...